Table 2.
Risk perceptions
| Survey Question | Response, n (%) |
| What do you tell HCV− potential recipients about the risk of HCV transmission from nonviremic (Ab+/NAT−) donors? (item denominator=107 a ) | |
| <5% | 68 (64) |
| 5%–25% | 16 (15) |
| 26%–50% | 3 (3) |
| >50% | 10 (9) |
| Do not discuss | 10 (9) |
| What do you tell HCV− potential recipients about the risk of chronic HCV infection after KTx from donors who are HCV Ab+/NAT+ (viremic) without DAA treatment? (item denominator=107 a ) | |
| <10% | 14 (13) |
| 10%–25% | 2 (2) |
| 26%–50% | 4 (4) |
| 51%–75% | 6 (6) |
| 76%–85% | 2 (2) |
| 86%–100% | 53 (50) |
| We do not discuss this possible risk | 26 (24) |
| In your view, what is the risk of chronic HCV infection due to treatment failure after KTx from donors who are HCV Ab+/NAT+ and appropriate DAA therapy? (item denominator=109 a ) | |
| <1% | 51 (47) |
| 1%–5% | 52 (48) |
| 6%–10% | 2 (2) |
| >10% | 4 (4) |
| How much reduction in waiting time (months) do you think justifies accepting a KTx from a donor who is HCV Ab+/NAT+ (viremic) for a recipient who is HCV–, versus waiting for another deceased donor organ? Mean (range) (item denominator=108a) | 18 (0–60) |
HCV, hepatitis C virus; Ab, antibody; NAT, nucleic acid testing; KTx, kidney transplant; DAA, direct-acting antiviral agent.
a
Indicates the item denominator, based on number of respondents, and accounting for contingent responses.